Investigational Phage Therapy Shows Positive Topline Results for Diabetic Foot Osteomyelitis
Phage 3D imageImage credit: Victor Padilla-Sanchez, PhD Yesterday, an Israeli-based company, BiomX, announced results from its phase 2 trial studying its investigational phage therapy, BX211, which was found to be safe, well-tolerated, and demonstrated a clinical benefit for treatment of diabetic foot osteomyelitis (DFO) associated with Staphylococcus aureus.1 Specifically, BX211 produced a sustained and statistically significant […]
Infectious Disease Treatments on FDA’s Watchlist for Q2 2025
As we enter the second quarter of 2025, the FDA is reviewing treatments in infectious disease. Novavax is seeking full approval for its COVID-19 vaccine, Merck’s monoclonal antibody for RSV prevention is under review, and Innoviva has applied an oral antibiotic for gonorrhea. Here is what to expect in the coming months. Novavax COVID-19 VaccinePDUFA […]
WHO Issues First Reports on Diagnostics, Therapies For Fungal Infections
Today, the World Health Organization (WHO) announced it had published 2 reports regarding therapies and diagnostics for fungal diseases. The reports were designed to address the gaps in testing and treatments, especially in low- and middle-income countries (LMICs). “Invasive fungal infections threaten the lives of the most vulnerable but countries lack the treatments needed to […]
Humanizing Monoclonal Antibodies for Mucormycosis Treatment
Researchers have developed VX-01, a humanized monoclonal antibody designed to target mucormycosis, a severe fungal infection predominantly affecting immunocompromised individuals. VX-01 enhances the host’s immune response and prevents fungal angioinvasion, offering a promising adjunctive treatment for this often fatal disease. Mucormycosis, caused by Mucorales fungi, poses significant risks, especially to those with weakened immune systems. […]
VX-01 Monoclonal Antibody Targets Mucormycosis by Blocking Angioinvasion
Researchers have developed VX-01, a humanized monoclonal antibody designed to target mucormycosis, a severe fungal infection predominantly affecting immunocompromised individuals. VX-01 enhances the host’s immune response and prevents fungal angioinvasion, offering a promising adjunctive treatment for this often fatal disease. Mucormycosis, caused by Mucorales fungi, poses significant risks, especially to those with weakened immune systems. […]
With HHS Layoffs, What Becomes of Public Health?
This is the second in a series looking at the reduction and restructuring of federal health services and how that will affect public health and infectious disease clinical care. This past Friday, the Department of Health and Human Services (HHS) announced it was going to reduce its workforce by laying off 10,000 full-time employees, and […]
Collaborative HCV Care with Pharmacists Could Address System-Level Treatment Barriers
Meghan Morris, PhD, MPH Credit: UCSF This news was originally posed on our sister site, HCPLive.com New research is shedding light on the importance of collaborative care for facilitating community-based point-of-diagnosis hepatitis C virus (HCV) treatment initiation among high-risk, marginalized patient populations.1 In the No One Waits (NOW) trial, a longitudinal partnership with a specialized, […]
FDA Grants Marketing Authorization For First Home Test for STIs
Sexual transmitted infections (STIs) continue to be a public health concern. Along with millions of cases overall being diagnosed every year, attached to STIs is stigma and fear, which may prevent or delay people from getting tested. However, a new test looks to reduce these concerns by adding a layer of privacy with the ability […]
Top 5 Infectious Disease News Stories Week of March 22-29
FDA Approves Gepotidacin (Blujepa) for Uncomplicated Urinary Tract Infections The FDA has approved gepotidacin (Blujepa), a new oral antibiotic for treating uncomplicated urinary tract infections (uUTIs) in females aged 12 and older. This approval marks the first new class of oral antibiotics for uUTIs in nearly 30 years. GSK’s gepotidacin was shown to be non-inferior […]
Clinical Implications, Study Takeaways of Gepotidacin For Uncomplicated UTIs
Earlier this week, the FDA approved GSK’s antibiotic, gepotidacin (Blujepa). The treatment is indicated for uncomplicated urinary tract infections (UTIs) in female patients aged at least 12 years and weighing at least 40 kg, and that are caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus and Enterococcus faecalis.1 Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with […]
